drugset / Trial / NCT04099589

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

NCT04099589 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant treatment model might benefit patients. So This prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive bladder urothelial carcinoma, then to improve the rate of complete pathological remission, survival and provide medical evidence.

Timeline

Start
2019-10-01
Primary completion
2022-10-01
Completion
2022-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody — —